Ultragenyx Pharmaceutical | RARE - Debt

Stock Price
20.46
Daily Change
-1.14 -5.28%
Monthly
-6.28%
Yearly
-48.44%
Q1 Forecast
20.70

Ultragenyx Pharmaceutical reported $33.83M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Immunic USD 0 0 Jun/2024
Insmed USD 727.89M 163.33M Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Karyopharm Therapeutics USD 264.09M 39.31M Sep/2024
Kyowa Hakko Kirin JPY 28.75B 5.04B Dec/2024
MacroGenics USD 37.01M 238K Sep/2025
Moderna USD 734M 7M Sep/2025
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025
Xoma USD 120.79M 3.27M Jun/2024